Granules India shares climb nearly 7% on USFDA nod for drug
The scrip advanced by 6.61% to end at Rs103.15 on BSE. Intra-day, it zoomed 10.18% to Rs106.60. On NSE, shares of the company surged 6.67% to close at Rs103.15
New Delhi:Shares of drug firm Granules India Thursday soared nearly 7% after the company’s subsidiary received approval from the US health regulator for Methylergonovine tablets, used for prevention and control of postpartum haemorrhage.
The scrip advanced by 6.61% to end at Rs103.15 on BSE. Intra-day, it zoomed 10.18% to Rs106.60. On NSE, shares of the company surged 6.67% to close at Rs103.15.
On the equity volume front, 8.75 lakh shares of the company were traded on BSE and over one crore shares changed hands on NSE during the day.
In a filing to the BSE, Granules India said, “the US Food and Drug Administration (US FDA) has approved its abbreviated new drug applications (ANDA) for Methylergonovine 0.2 mg tablets.
The ANDA was filed by Granules Pharmaceuticals Inc, a wholly owned subsidiary of Granules India Ltd”.
Editor's Picks »
- KTR: The protean leading TRS’ pink brigade in Telangana
- Competition Commission clears Tata Sponge’s acquisition of Usha Martin
- BJP loses vote share big time, but not all to Congress
- Flipkart to invest in furniture, groceries; claims to be a market leader in e-commerce
- Sriram Venkataraman is the new Flipkart COO
- Steel stocks get winter chill as China demand issues resurface
- Why Uday Kotak’s defiance is scaring his bank’s investors
- Exit RBI governor Urjit Patel, enter wrath of the markets?
- The government has a troubling message for minority shareholders
- Opec-allies’ output cut may not amount to big shift in oil prices